Showing 1 - 20 results of 30,550 for search '(( 100 ((teer decrease) OR (greater decrease)) ) OR ( 50 ((_ decrease) OR (a decrease)) ))*', query time: 0.86s Refine Results
  1. 1
  2. 2

    Substance P decreases PRL immunoreactivity in human epidermis. by Ewan A. Langan (405804)

    Published 2013
    “…PRL IR was measured using Image J software, showing that (C) epidermal PRL IR was significantly decreased by 100 nM Substance P treatment (p = 0.009). …”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Hemodiafiltration Decreases Serum Levels of Inflammatory Mediators in Severe Leptospirosis: A Prospective Study by Sérgio Aparecido Cleto (3143949)

    Published 2016
    “…However, post-admission decreases in the serum levels of interleukin (IL)-17, IL-7, and monocyte chemoattractant protein-1 were significantly greater in the SLEDf group. …”
  8. 8
  9. 9

    IL-18 decreases TEER in Caco2 monolayers. by Ossama Allam (5043434)

    Published 2018
    “…<p>The TEER was measured during 24 hours after addition of 10 ng/ml of IL-18, 10 ng/ml IL-1β or 100 ng/ml Tat to the cell monolayers. …”
  10. 10
  11. 11
  12. 12
  13. 13

    Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

    Published 2009
    “…<p>(A) RFF is decreased by alterations in heart rate. …”
  14. 14

    Decreased macrophage recruitment correlates with decreased angiogenesis. by Johanna R. Reed (306158)

    Published 2013
    “…<p>A) Quantification of BrdU incorporation demonstrates that decreased macrophage infiltration does not significantly correlate with a change in epithelial cell proliferation (N.S. = not significant). …”
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  20. 20